Home --- Discovery --- Pipeline

Pipeline

L’attuale portfolio delle molecole di Nerviano Medical Sciences comprende composti antitumorali in fase clinica o in avanzato stadio di sviluppo preclinico, oltre ai progetti di ricerca. Diversi programmi sono condotti nell'ambito di alleanze strategiche.

ENCORAFENIB
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENTRECTINIB
PRECLINICAL PHASE I PHASE II PHASE III
72% PHASE II
MILCICLIB
PRECLINICAL PHASE I PHASE II PHASE III
62% PHASE II
S81694
(NMS-P153, MPS1)
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
PCM-075
(NMS-P937, PLK1)
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
ADC-Payload (PNU-682)
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
ADC-Payload (NMS-P945)
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
Kinase inhibitor
program
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
 
PRECLINICAL PHASE I PHASE II PHASE III
0% PRECLINICAL
DANUSERTIB (AURORA)
PRECLINICAL PHASE I PHASE II PHASE III
59% PHASE II
NMS-P088
(FLT3, KIT, CSF1R)
PRECLINICAL PHASE I PHASE II PHASE III
21% PRECLINICAL
NMS-P293
(PARP1)
PRECLINICAL PHASE I PHASE II PHASE III
18% PRECLINICAL
DISCOVERY programs:
PRECLINICAL PHASE I PHASE II PHASE III
0% PRECLINICAL
• Pre-PC
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
• Lead optimization
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
• Early projects
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
ADC-PAYLOAD
platform
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL